SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

SNDL Inc.NASDAQ: SNDL

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of CA$64.01M fell 1.3% year over year, ahead of the -26.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 6.7% from the prior quarter. Over 3 fiscal years it compounded at -18.6% a year.

Context

  • Operating expenses amounted to 27.8% of revenue in FY2025, down 9.6 pp from a year earlier.
  • Operating expenses increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -1.3% holds above the trailing-twelve-month pace of -26.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$64.01M+6.7% QoQ
Last fiscal yearDec 2025
CA$263.07M-23.6% YoY
LTMMar 2026
CA$262.24M-26.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.3%——
1 year-23.6%——
3-year CAGR-18.6%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

CAD · from the income statement

Latest · FY2025
263.07M CAD
Year-over-year change
-23.6%
4-year CAGR
+20.4%

Operating Expenses vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.0% is the 10th highest of 11, against a peer median of +5.9%.
  • Operating expenses amounts to 28.0% of revenue for SNDL, versus a peer median of 68.3%.
SNDL Competitors
Operating Expenses for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$350.61M USD-4.1%+4.5%68.3%
SNDLSNDL Inc.LTM Mar 2026CA$262.24M CAD-26.0%-18.6%28.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$229.6M USD-49.2%-28.0%33.9%
EOLSEvolus, Inc.LTM Mar 2026$226.67M USD-0.4%+14.1%75.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$201.51M USD+41.1%+18.6%—
ESPREsperion Therapeutics, Inc.LTM Mar 2026$196.07M USD-6.4%-2.1%46.9%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$182.66M USD+16.7%-21.0%78.6%
CMPSCOMPASS Pathways plcLTM Mar 2026$172.25M USD-9.0%+17.5%—
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$87.79M USD+12.2%+11.3%174.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$47.9M USD+53.4%+9.6%—
SIGASIGA Technologies, Inc.LTM Mar 2026$40.65M USD+14.0%-10.6%43.3%
Peer median (excluding SNDL) —+5.9%+7.1%68.3%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.